Outset Medical Analyst Ratings
RBC Capital Maintains Outset Medical(OM.US) With Hold Rating, Maintains Target Price $3
Stifel Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $6
Outset Medical's Financial Strength and Sales Growth: A Buy Rating From Rick Wise
BTIG Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $4
Outset Medical (OM) Receives a Buy From BTIG
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Stifel Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $6
TD Cowen Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $3
RBC Capital Maintains Outset Medical(OM.US) With Hold Rating, Maintains Target Price $3
BTIG Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $4
TD Cowen Maintains Outset Medical(OM.US) With Buy Rating, Cuts Target Price to $3
Outset Medical's Strong Q3 Performance and Strategic Expansion Justifies Buy Rating
RBC Capital Downgrades Outset Medical(OM.US) to Hold Rating, Cuts Target Price to $3
RBC Capital Remains a Hold on Outset Medical (OM)
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Outset Medical Price Target Cut to $3.00/Share From $6.00 by RBC Capital
TD Cowen Maintains Buy on Outset Medical, Lowers Price Target to $3
Outset Medical Analyst Ratings
RBC Capital Reaffirms Their Hold Rating on Outset Medical (OM)